-+ 0.00%
-+ 0.00%
-+ 0.00%

Novo Nordisk says real-world OCTANE study shows 4.1% average weight loss after switch to Wegovy pill

PUBT·09/30/2026 09:51:00
Listen to the news
Novo Nordisk says real-world OCTANE study shows 4.1% average weight loss after switch to Wegovy pill
  • Novo Nordisk disclosed real-world OCTANE study results already presented at EASD 2026 on Sept. 30 in Milan.
  • Patients switching from injectable GLP-1 weight-loss drugs to once-daily Wegovy pill continued to lose weight over three months.
  • The analysis also showed a meaningful share moved below the clinical obesity threshold, supporting the pill as an alternative for some users.
  • Wegovy pill has launched in the US, UAE, UK, Germany, with additional market launches planned in coming quarters.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.